nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxepin—CYP2C19—Ifosfamide—testicular cancer	0.0584	0.146	CbGbCtD
Doxepin—ADRA1B—vas deferens—testicular cancer	0.0513	0.512	CbGeAlD
Doxepin—CYP2C9—Ifosfamide—testicular cancer	0.0485	0.121	CbGbCtD
Doxepin—ABCB1—Dactinomycin—testicular cancer	0.0399	0.0995	CbGbCtD
Doxepin—CYP3A4—Ifosfamide—testicular cancer	0.0282	0.0704	CbGbCtD
Doxepin—CYP1A2—Etoposide—testicular cancer	0.0257	0.0642	CbGbCtD
Doxepin—ABCB1—Vinblastine—testicular cancer	0.025	0.0624	CbGbCtD
Doxepin—CYP2C9—Cisplatin—testicular cancer	0.0236	0.0589	CbGbCtD
Doxepin—CYP2D6—Vinblastine—testicular cancer	0.0235	0.0588	CbGbCtD
Doxepin—ABCB1—Cisplatin—testicular cancer	0.0229	0.0572	CbGbCtD
Doxepin—ABCB1—Etoposide—testicular cancer	0.0225	0.0562	CbGbCtD
Doxepin—ABCB1—Doxorubicin—testicular cancer	0.0154	0.0383	CbGbCtD
Doxepin—CYP3A4—Vinblastine—testicular cancer	0.015	0.0374	CbGbCtD
Doxepin—ABCB1—Methotrexate—testicular cancer	0.0149	0.0371	CbGbCtD
Doxepin—CYP2D6—Doxorubicin—testicular cancer	0.0145	0.0361	CbGbCtD
Doxepin—CYP3A4—Etoposide—testicular cancer	0.0135	0.0337	CbGbCtD
Doxepin—CYP3A4—Doxorubicin—testicular cancer	0.0092	0.023	CbGbCtD
Doxepin—HTR2A—vein—testicular cancer	0.00791	0.079	CbGeAlD
Doxepin—CHRM4—testis—testicular cancer	0.00282	0.0282	CbGeAlD
Doxepin—KCNH2—seminal vesicle—testicular cancer	0.0021	0.021	CbGeAlD
Doxepin—ADRA2C—seminal vesicle—testicular cancer	0.00207	0.0207	CbGeAlD
Doxepin—SLC6A2—gonad—testicular cancer	0.00169	0.0169	CbGeAlD
Doxepin—HRH2—lymph node—testicular cancer	0.00168	0.0167	CbGeAlD
Doxepin—ADRA2A—seminal vesicle—testicular cancer	0.00165	0.0165	CbGeAlD
Doxepin—HTR2A—embryo—testicular cancer	0.0015	0.0149	CbGeAlD
Doxepin—CHRM3—female gonad—testicular cancer	0.00139	0.0139	CbGeAlD
Doxepin—CHRM3—testis—testicular cancer	0.00123	0.0123	CbGeAlD
Doxepin—KCNH2—female gonad—testicular cancer	0.00123	0.0123	CbGeAlD
Doxepin—SLC6A2—testis—testicular cancer	0.00122	0.0122	CbGeAlD
Doxepin—ADRA2C—female gonad—testicular cancer	0.00122	0.0122	CbGeAlD
Doxepin—ADRA2A—gonad—testicular cancer	0.0012	0.0119	CbGeAlD
Doxepin—ORM1—lymph node—testicular cancer	0.00118	0.0118	CbGeAlD
Doxepin—DRD2—testis—testicular cancer	0.00111	0.0111	CbGeAlD
Doxepin—KCNH2—testis—testicular cancer	0.00109	0.0109	CbGeAlD
Doxepin—ADRA2C—testis—testicular cancer	0.00108	0.0108	CbGeAlD
Doxepin—HTR2A—gonad—testicular cancer	0.00102	0.0101	CbGeAlD
Doxepin—HTR2B—lymph node—testicular cancer	0.000995	0.00993	CbGeAlD
Doxepin—HRH1—female gonad—testicular cancer	0.000989	0.00987	CbGeAlD
Doxepin—ABCB1—embryo—testicular cancer	0.000982	0.0098	CbGeAlD
Doxepin—ADRA2A—female gonad—testicular cancer	0.000972	0.0097	CbGeAlD
Doxepin—ABCB1—seminal vesicle—testicular cancer	0.000922	0.0092	CbGeAlD
Doxepin—SLC6A2—lymph node—testicular cancer	0.000884	0.00882	CbGeAlD
Doxepin—HRH1—testis—testicular cancer	0.000877	0.00876	CbGeAlD
Doxepin—ADRA2A—testis—testicular cancer	0.000862	0.0086	CbGeAlD
Doxepin—KCNH2—lymph node—testicular cancer	0.000793	0.00792	CbGeAlD
Doxepin—ADRA2C—lymph node—testicular cancer	0.000783	0.00781	CbGeAlD
Doxepin—CYP2D6—female gonad—testicular cancer	0.000753	0.00751	CbGeAlD
Doxepin—HTR2A—testis—testicular cancer	0.000733	0.00731	CbGeAlD
Doxepin—CYP2D6—testis—testicular cancer	0.000668	0.00666	CbGeAlD
Doxepin—ABCB1—gonad—testicular cancer	0.000666	0.00665	CbGeAlD
Doxepin—HRH1—lymph node—testicular cancer	0.000636	0.00635	CbGeAlD
Doxepin—ADRA2A—lymph node—testicular cancer	0.000625	0.00623	CbGeAlD
Doxepin—ABCB1—female gonad—testicular cancer	0.000541	0.0054	CbGeAlD
Doxepin—ABCB1—testis—testicular cancer	0.00048	0.00479	CbGeAlD
Doxepin—ABCB1—lymph node—testicular cancer	0.000348	0.00347	CbGeAlD
Doxepin—Abdominal pain—Etoposide—testicular cancer	0.000314	0.000636	CcSEcCtD
Doxepin—Body temperature increased—Etoposide—testicular cancer	0.000314	0.000636	CcSEcCtD
Doxepin—Urinary tract infection—Doxorubicin—testicular cancer	0.000314	0.000636	CcSEcCtD
Doxepin—Hepatitis—Epirubicin—testicular cancer	0.000313	0.000634	CcSEcCtD
Doxepin—Eye disorder—Methotrexate—testicular cancer	0.000313	0.000634	CcSEcCtD
Doxepin—Tinnitus—Methotrexate—testicular cancer	0.000312	0.000632	CcSEcCtD
Doxepin—Hypoaesthesia—Epirubicin—testicular cancer	0.000311	0.000631	CcSEcCtD
Doxepin—Asthenia—Cisplatin—testicular cancer	0.000311	0.00063	CcSEcCtD
Doxepin—Pharyngitis—Epirubicin—testicular cancer	0.000311	0.00063	CcSEcCtD
Doxepin—Cardiac disorder—Methotrexate—testicular cancer	0.00031	0.000629	CcSEcCtD
Doxepin—Sweating—Doxorubicin—testicular cancer	0.000309	0.000627	CcSEcCtD
Doxepin—Urinary tract disorder—Epirubicin—testicular cancer	0.000309	0.000627	CcSEcCtD
Doxepin—Oedema peripheral—Epirubicin—testicular cancer	0.000308	0.000625	CcSEcCtD
Doxepin—Connective tissue disorder—Epirubicin—testicular cancer	0.000308	0.000623	CcSEcCtD
Doxepin—Urethral disorder—Epirubicin—testicular cancer	0.000307	0.000622	CcSEcCtD
Doxepin—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000305	0.000618	CcSEcCtD
Doxepin—Angiopathy—Methotrexate—testicular cancer	0.000303	0.000615	CcSEcCtD
Doxepin—Sinusitis—Doxorubicin—testicular cancer	0.000303	0.000613	CcSEcCtD
Doxepin—Immune system disorder—Methotrexate—testicular cancer	0.000302	0.000612	CcSEcCtD
Doxepin—Mediastinal disorder—Methotrexate—testicular cancer	0.000301	0.000611	CcSEcCtD
Doxepin—Agranulocytosis—Doxorubicin—testicular cancer	0.000301	0.00061	CcSEcCtD
Doxepin—Chills—Methotrexate—testicular cancer	0.0003	0.000608	CcSEcCtD
Doxepin—Nausea—Ifosfamide—testicular cancer	0.000298	0.000605	CcSEcCtD
Doxepin—Diarrhoea—Cisplatin—testicular cancer	0.000296	0.000601	CcSEcCtD
Doxepin—Alopecia—Methotrexate—testicular cancer	0.000295	0.000599	CcSEcCtD
Doxepin—Bradycardia—Doxorubicin—testicular cancer	0.000295	0.000598	CcSEcCtD
Doxepin—Mental disorder—Methotrexate—testicular cancer	0.000293	0.000594	CcSEcCtD
Doxepin—Eye disorder—Epirubicin—testicular cancer	0.000292	0.000593	CcSEcCtD
Doxepin—Hypersensitivity—Etoposide—testicular cancer	0.000292	0.000592	CcSEcCtD
Doxepin—Tinnitus—Epirubicin—testicular cancer	0.000292	0.000592	CcSEcCtD
Doxepin—Erythema—Methotrexate—testicular cancer	0.000291	0.00059	CcSEcCtD
Doxepin—Malnutrition—Methotrexate—testicular cancer	0.000291	0.00059	CcSEcCtD
Doxepin—Flushing—Epirubicin—testicular cancer	0.00029	0.000589	CcSEcCtD
Doxepin—Cardiac disorder—Epirubicin—testicular cancer	0.00029	0.000589	CcSEcCtD
Doxepin—Hepatitis—Doxorubicin—testicular cancer	0.00029	0.000587	CcSEcCtD
Doxepin—Hypoaesthesia—Doxorubicin—testicular cancer	0.000288	0.000584	CcSEcCtD
Doxepin—Pharyngitis—Doxorubicin—testicular cancer	0.000287	0.000583	CcSEcCtD
Doxepin—Urinary tract disorder—Doxorubicin—testicular cancer	0.000286	0.00058	CcSEcCtD
Doxepin—Oedema peripheral—Doxorubicin—testicular cancer	0.000285	0.000578	CcSEcCtD
Doxepin—Dysgeusia—Methotrexate—testicular cancer	0.000285	0.000578	CcSEcCtD
Doxepin—Asthenia—Etoposide—testicular cancer	0.000285	0.000577	CcSEcCtD
Doxepin—Connective tissue disorder—Doxorubicin—testicular cancer	0.000285	0.000577	CcSEcCtD
Doxepin—Angiopathy—Epirubicin—testicular cancer	0.000284	0.000576	CcSEcCtD
Doxepin—Urethral disorder—Doxorubicin—testicular cancer	0.000284	0.000575	CcSEcCtD
Doxepin—Immune system disorder—Epirubicin—testicular cancer	0.000283	0.000573	CcSEcCtD
Doxepin—Mediastinal disorder—Epirubicin—testicular cancer	0.000282	0.000572	CcSEcCtD
Doxepin—Back pain—Methotrexate—testicular cancer	0.000282	0.000571	CcSEcCtD
Doxepin—Chills—Epirubicin—testicular cancer	0.000281	0.000569	CcSEcCtD
Doxepin—Pruritus—Etoposide—testicular cancer	0.000281	0.000569	CcSEcCtD
Doxepin—Arrhythmia—Epirubicin—testicular cancer	0.00028	0.000567	CcSEcCtD
Doxepin—Alopecia—Epirubicin—testicular cancer	0.000277	0.000561	CcSEcCtD
Doxepin—Vomiting—Cisplatin—testicular cancer	0.000275	0.000558	CcSEcCtD
Doxepin—Vision blurred—Methotrexate—testicular cancer	0.000274	0.000556	CcSEcCtD
Doxepin—Mental disorder—Epirubicin—testicular cancer	0.000274	0.000556	CcSEcCtD
Doxepin—Rash—Cisplatin—testicular cancer	0.000273	0.000553	CcSEcCtD
Doxepin—Dermatitis—Cisplatin—testicular cancer	0.000273	0.000553	CcSEcCtD
Doxepin—Malnutrition—Epirubicin—testicular cancer	0.000272	0.000552	CcSEcCtD
Doxepin—Erythema—Epirubicin—testicular cancer	0.000272	0.000552	CcSEcCtD
Doxepin—Diarrhoea—Etoposide—testicular cancer	0.000271	0.00055	CcSEcCtD
Doxepin—Eye disorder—Doxorubicin—testicular cancer	0.000271	0.000549	CcSEcCtD
Doxepin—Ill-defined disorder—Methotrexate—testicular cancer	0.00027	0.000548	CcSEcCtD
Doxepin—Tinnitus—Doxorubicin—testicular cancer	0.00027	0.000547	CcSEcCtD
Doxepin—Anaemia—Methotrexate—testicular cancer	0.000269	0.000545	CcSEcCtD
Doxepin—Flushing—Doxorubicin—testicular cancer	0.000269	0.000545	CcSEcCtD
Doxepin—Cardiac disorder—Doxorubicin—testicular cancer	0.000269	0.000545	CcSEcCtD
Doxepin—Flatulence—Epirubicin—testicular cancer	0.000268	0.000544	CcSEcCtD
Doxepin—Tension—Epirubicin—testicular cancer	0.000267	0.000542	CcSEcCtD
Doxepin—Dysgeusia—Epirubicin—testicular cancer	0.000267	0.000541	CcSEcCtD
Doxepin—Nervousness—Epirubicin—testicular cancer	0.000265	0.000536	CcSEcCtD
Doxepin—Back pain—Epirubicin—testicular cancer	0.000264	0.000534	CcSEcCtD
Doxepin—Angiopathy—Doxorubicin—testicular cancer	0.000263	0.000533	CcSEcCtD
Doxepin—Malaise—Methotrexate—testicular cancer	0.000263	0.000532	CcSEcCtD
Doxepin—Dizziness—Etoposide—testicular cancer	0.000262	0.000532	CcSEcCtD
Doxepin—Muscle spasms—Epirubicin—testicular cancer	0.000262	0.000531	CcSEcCtD
Doxepin—Immune system disorder—Doxorubicin—testicular cancer	0.000262	0.00053	CcSEcCtD
Doxepin—Vertigo—Methotrexate—testicular cancer	0.000262	0.00053	CcSEcCtD
Doxepin—Mediastinal disorder—Doxorubicin—testicular cancer	0.000261	0.000529	CcSEcCtD
Doxepin—Leukopenia—Methotrexate—testicular cancer	0.000261	0.000528	CcSEcCtD
Doxepin—Chills—Doxorubicin—testicular cancer	0.00026	0.000527	CcSEcCtD
Doxepin—Arrhythmia—Doxorubicin—testicular cancer	0.000259	0.000524	CcSEcCtD
Doxepin—Nausea—Cisplatin—testicular cancer	0.000257	0.000521	CcSEcCtD
Doxepin—Vision blurred—Epirubicin—testicular cancer	0.000257	0.00052	CcSEcCtD
Doxepin—Alopecia—Doxorubicin—testicular cancer	0.000256	0.000519	CcSEcCtD
Doxepin—Cough—Methotrexate—testicular cancer	0.000254	0.000515	CcSEcCtD
Doxepin—Mental disorder—Doxorubicin—testicular cancer	0.000254	0.000514	CcSEcCtD
Doxepin—Ill-defined disorder—Epirubicin—testicular cancer	0.000253	0.000512	CcSEcCtD
Doxepin—Convulsion—Methotrexate—testicular cancer	0.000252	0.000511	CcSEcCtD
Doxepin—Vomiting—Etoposide—testicular cancer	0.000252	0.000511	CcSEcCtD
Doxepin—Malnutrition—Doxorubicin—testicular cancer	0.000252	0.000511	CcSEcCtD
Doxepin—Erythema—Doxorubicin—testicular cancer	0.000252	0.000511	CcSEcCtD
Doxepin—Anaemia—Epirubicin—testicular cancer	0.000252	0.00051	CcSEcCtD
Doxepin—Agitation—Epirubicin—testicular cancer	0.00025	0.000508	CcSEcCtD
Doxepin—Rash—Etoposide—testicular cancer	0.00025	0.000507	CcSEcCtD
Doxepin—Dermatitis—Etoposide—testicular cancer	0.00025	0.000507	CcSEcCtD
Doxepin—Headache—Etoposide—testicular cancer	0.000248	0.000504	CcSEcCtD
Doxepin—Flatulence—Doxorubicin—testicular cancer	0.000248	0.000504	CcSEcCtD
Doxepin—Arthralgia—Methotrexate—testicular cancer	0.000248	0.000502	CcSEcCtD
Doxepin—Chest pain—Methotrexate—testicular cancer	0.000248	0.000502	CcSEcCtD
Doxepin—Myalgia—Methotrexate—testicular cancer	0.000248	0.000502	CcSEcCtD
Doxepin—Tension—Doxorubicin—testicular cancer	0.000247	0.000501	CcSEcCtD
Doxepin—Dysgeusia—Doxorubicin—testicular cancer	0.000247	0.0005	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000246	0.000499	CcSEcCtD
Doxepin—Malaise—Epirubicin—testicular cancer	0.000246	0.000498	CcSEcCtD
Doxepin—Discomfort—Methotrexate—testicular cancer	0.000245	0.000496	CcSEcCtD
Doxepin—Nervousness—Doxorubicin—testicular cancer	0.000245	0.000496	CcSEcCtD
Doxepin—Vertigo—Epirubicin—testicular cancer	0.000245	0.000496	CcSEcCtD
Doxepin—Syncope—Epirubicin—testicular cancer	0.000244	0.000495	CcSEcCtD
Doxepin—Leukopenia—Epirubicin—testicular cancer	0.000244	0.000494	CcSEcCtD
Doxepin—Back pain—Doxorubicin—testicular cancer	0.000244	0.000494	CcSEcCtD
Doxepin—Muscle spasms—Doxorubicin—testicular cancer	0.000242	0.000491	CcSEcCtD
Doxepin—Palpitations—Epirubicin—testicular cancer	0.000241	0.000488	CcSEcCtD
Doxepin—Confusional state—Methotrexate—testicular cancer	0.00024	0.000486	CcSEcCtD
Doxepin—Loss of consciousness—Epirubicin—testicular cancer	0.000239	0.000485	CcSEcCtD
Doxepin—Cough—Epirubicin—testicular cancer	0.000238	0.000482	CcSEcCtD
Doxepin—Vision blurred—Doxorubicin—testicular cancer	0.000238	0.000482	CcSEcCtD
Doxepin—Convulsion—Epirubicin—testicular cancer	0.000236	0.000478	CcSEcCtD
Doxepin—Infection—Methotrexate—testicular cancer	0.000236	0.000478	CcSEcCtD
Doxepin—Nausea—Etoposide—testicular cancer	0.000236	0.000478	CcSEcCtD
Doxepin—Hypertension—Epirubicin—testicular cancer	0.000235	0.000477	CcSEcCtD
Doxepin—Ill-defined disorder—Doxorubicin—testicular cancer	0.000234	0.000474	CcSEcCtD
Doxepin—Nervous system disorder—Methotrexate—testicular cancer	0.000233	0.000472	CcSEcCtD
Doxepin—Anaemia—Doxorubicin—testicular cancer	0.000233	0.000472	CcSEcCtD
Doxepin—Thrombocytopenia—Methotrexate—testicular cancer	0.000233	0.000472	CcSEcCtD
Doxepin—Arthralgia—Epirubicin—testicular cancer	0.000232	0.00047	CcSEcCtD
Doxepin—Chest pain—Epirubicin—testicular cancer	0.000232	0.00047	CcSEcCtD
Doxepin—Myalgia—Epirubicin—testicular cancer	0.000232	0.00047	CcSEcCtD
Doxepin—Agitation—Doxorubicin—testicular cancer	0.000232	0.00047	CcSEcCtD
Doxepin—Anxiety—Epirubicin—testicular cancer	0.000231	0.000469	CcSEcCtD
Doxepin—Skin disorder—Methotrexate—testicular cancer	0.000231	0.000468	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.00023	0.000467	CcSEcCtD
Doxepin—Hyperhidrosis—Methotrexate—testicular cancer	0.00023	0.000466	CcSEcCtD
Doxepin—Discomfort—Epirubicin—testicular cancer	0.000229	0.000465	CcSEcCtD
Doxepin—Malaise—Doxorubicin—testicular cancer	0.000227	0.000461	CcSEcCtD
Doxepin—Dry mouth—Epirubicin—testicular cancer	0.000227	0.00046	CcSEcCtD
Doxepin—Vertigo—Doxorubicin—testicular cancer	0.000226	0.000459	CcSEcCtD
Doxepin—Anorexia—Methotrexate—testicular cancer	0.000226	0.000459	CcSEcCtD
Doxepin—Syncope—Doxorubicin—testicular cancer	0.000226	0.000458	CcSEcCtD
Doxepin—Leukopenia—Doxorubicin—testicular cancer	0.000226	0.000457	CcSEcCtD
Doxepin—Confusional state—Epirubicin—testicular cancer	0.000224	0.000454	CcSEcCtD
Doxepin—Palpitations—Doxorubicin—testicular cancer	0.000223	0.000452	CcSEcCtD
Doxepin—Oedema—Epirubicin—testicular cancer	0.000222	0.000451	CcSEcCtD
Doxepin—Hypotension—Methotrexate—testicular cancer	0.000222	0.00045	CcSEcCtD
Doxepin—Loss of consciousness—Doxorubicin—testicular cancer	0.000222	0.000449	CcSEcCtD
Doxepin—Infection—Epirubicin—testicular cancer	0.000221	0.000448	CcSEcCtD
Doxepin—Cough—Doxorubicin—testicular cancer	0.00022	0.000446	CcSEcCtD
Doxepin—Shock—Epirubicin—testicular cancer	0.000219	0.000443	CcSEcCtD
Doxepin—Convulsion—Doxorubicin—testicular cancer	0.000218	0.000443	CcSEcCtD
Doxepin—Nervous system disorder—Epirubicin—testicular cancer	0.000218	0.000442	CcSEcCtD
Doxepin—Thrombocytopenia—Epirubicin—testicular cancer	0.000218	0.000441	CcSEcCtD
Doxepin—Hypertension—Doxorubicin—testicular cancer	0.000218	0.000441	CcSEcCtD
Doxepin—Tachycardia—Epirubicin—testicular cancer	0.000217	0.00044	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000216	0.000439	CcSEcCtD
Doxepin—Skin disorder—Epirubicin—testicular cancer	0.000216	0.000438	CcSEcCtD
Doxepin—Hyperhidrosis—Epirubicin—testicular cancer	0.000215	0.000436	CcSEcCtD
Doxepin—Insomnia—Methotrexate—testicular cancer	0.000215	0.000436	CcSEcCtD
Doxepin—Chest pain—Doxorubicin—testicular cancer	0.000215	0.000435	CcSEcCtD
Doxepin—Myalgia—Doxorubicin—testicular cancer	0.000215	0.000435	CcSEcCtD
Doxepin—Arthralgia—Doxorubicin—testicular cancer	0.000215	0.000435	CcSEcCtD
Doxepin—Anxiety—Doxorubicin—testicular cancer	0.000214	0.000434	CcSEcCtD
Doxepin—Paraesthesia—Methotrexate—testicular cancer	0.000213	0.000432	CcSEcCtD
Doxepin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000213	0.000432	CcSEcCtD
Doxepin—Discomfort—Doxorubicin—testicular cancer	0.000212	0.00043	CcSEcCtD
Doxepin—Anorexia—Epirubicin—testicular cancer	0.000212	0.00043	CcSEcCtD
Doxepin—Dyspnoea—Methotrexate—testicular cancer	0.000212	0.000429	CcSEcCtD
Doxepin—Somnolence—Methotrexate—testicular cancer	0.000211	0.000428	CcSEcCtD
Doxepin—Dry mouth—Doxorubicin—testicular cancer	0.00021	0.000425	CcSEcCtD
Doxepin—Dyspepsia—Methotrexate—testicular cancer	0.000209	0.000424	CcSEcCtD
Doxepin—Hypotension—Epirubicin—testicular cancer	0.000208	0.000421	CcSEcCtD
Doxepin—Confusional state—Doxorubicin—testicular cancer	0.000207	0.000421	CcSEcCtD
Doxepin—Decreased appetite—Methotrexate—testicular cancer	0.000207	0.000419	CcSEcCtD
Doxepin—Oedema—Doxorubicin—testicular cancer	0.000206	0.000417	CcSEcCtD
Doxepin—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000205	0.000416	CcSEcCtD
Doxepin—Fatigue—Methotrexate—testicular cancer	0.000205	0.000415	CcSEcCtD
Doxepin—Infection—Doxorubicin—testicular cancer	0.000204	0.000414	CcSEcCtD
Doxepin—Pain—Methotrexate—testicular cancer	0.000203	0.000412	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000203	0.000411	CcSEcCtD
Doxepin—Shock—Doxorubicin—testicular cancer	0.000202	0.00041	CcSEcCtD
Doxepin—Nervous system disorder—Doxorubicin—testicular cancer	0.000202	0.000409	CcSEcCtD
Doxepin—Thrombocytopenia—Doxorubicin—testicular cancer	0.000201	0.000408	CcSEcCtD
Doxepin—Insomnia—Epirubicin—testicular cancer	0.000201	0.000408	CcSEcCtD
Doxepin—Tachycardia—Doxorubicin—testicular cancer	0.000201	0.000407	CcSEcCtD
Doxepin—Skin disorder—Doxorubicin—testicular cancer	0.0002	0.000405	CcSEcCtD
Doxepin—Paraesthesia—Epirubicin—testicular cancer	0.0002	0.000405	CcSEcCtD
Doxepin—Hyperhidrosis—Doxorubicin—testicular cancer	0.000199	0.000403	CcSEcCtD
Doxepin—Dyspnoea—Epirubicin—testicular cancer	0.000198	0.000402	CcSEcCtD
Doxepin—Somnolence—Epirubicin—testicular cancer	0.000198	0.000401	CcSEcCtD
Doxepin—Anorexia—Doxorubicin—testicular cancer	0.000196	0.000398	CcSEcCtD
Doxepin—Feeling abnormal—Methotrexate—testicular cancer	0.000196	0.000397	CcSEcCtD
Doxepin—Dyspepsia—Epirubicin—testicular cancer	0.000196	0.000397	CcSEcCtD
Doxepin—Gastrointestinal pain—Methotrexate—testicular cancer	0.000194	0.000394	CcSEcCtD
Doxepin—Decreased appetite—Epirubicin—testicular cancer	0.000193	0.000392	CcSEcCtD
Doxepin—Hypotension—Doxorubicin—testicular cancer	0.000192	0.00039	CcSEcCtD
Doxepin—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000192	0.000389	CcSEcCtD
Doxepin—Fatigue—Epirubicin—testicular cancer	0.000192	0.000389	CcSEcCtD
Doxepin—Constipation—Epirubicin—testicular cancer	0.00019	0.000385	CcSEcCtD
Doxepin—Pain—Epirubicin—testicular cancer	0.00019	0.000385	CcSEcCtD
Doxepin—Urticaria—Methotrexate—testicular cancer	0.000189	0.000383	CcSEcCtD
Doxepin—Abdominal pain—Methotrexate—testicular cancer	0.000188	0.000381	CcSEcCtD
Doxepin—Body temperature increased—Methotrexate—testicular cancer	0.000188	0.000381	CcSEcCtD
Doxepin—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000187	0.00038	CcSEcCtD
Doxepin—Insomnia—Doxorubicin—testicular cancer	0.000186	0.000377	CcSEcCtD
Doxepin—Paraesthesia—Doxorubicin—testicular cancer	0.000185	0.000374	CcSEcCtD
Doxepin—Dyspnoea—Doxorubicin—testicular cancer	0.000183	0.000372	CcSEcCtD
Doxepin—Feeling abnormal—Epirubicin—testicular cancer	0.000183	0.000371	CcSEcCtD
Doxepin—Somnolence—Doxorubicin—testicular cancer	0.000183	0.000371	CcSEcCtD
Doxepin—Gastrointestinal pain—Epirubicin—testicular cancer	0.000182	0.000369	CcSEcCtD
Doxepin—Dyspepsia—Doxorubicin—testicular cancer	0.000181	0.000367	CcSEcCtD
Doxepin—Decreased appetite—Doxorubicin—testicular cancer	0.000179	0.000363	CcSEcCtD
Doxepin—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000178	0.00036	CcSEcCtD
Doxepin—Fatigue—Doxorubicin—testicular cancer	0.000177	0.00036	CcSEcCtD
Doxepin—Urticaria—Epirubicin—testicular cancer	0.000177	0.000358	CcSEcCtD
Doxepin—Pain—Doxorubicin—testicular cancer	0.000176	0.000357	CcSEcCtD
Doxepin—Constipation—Doxorubicin—testicular cancer	0.000176	0.000357	CcSEcCtD
Doxepin—Abdominal pain—Epirubicin—testicular cancer	0.000176	0.000356	CcSEcCtD
Doxepin—Body temperature increased—Epirubicin—testicular cancer	0.000176	0.000356	CcSEcCtD
Doxepin—Hypersensitivity—Methotrexate—testicular cancer	0.000175	0.000355	CcSEcCtD
Doxepin—Asthenia—Methotrexate—testicular cancer	0.00017	0.000346	CcSEcCtD
Doxepin—Feeling abnormal—Doxorubicin—testicular cancer	0.00017	0.000344	CcSEcCtD
Doxepin—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000168	0.000341	CcSEcCtD
Doxepin—Pruritus—Methotrexate—testicular cancer	0.000168	0.000341	CcSEcCtD
Doxepin—Hypersensitivity—Epirubicin—testicular cancer	0.000164	0.000332	CcSEcCtD
Doxepin—Urticaria—Doxorubicin—testicular cancer	0.000163	0.000331	CcSEcCtD
Doxepin—Abdominal pain—Doxorubicin—testicular cancer	0.000163	0.00033	CcSEcCtD
Doxepin—Body temperature increased—Doxorubicin—testicular cancer	0.000163	0.00033	CcSEcCtD
Doxepin—Diarrhoea—Methotrexate—testicular cancer	0.000163	0.00033	CcSEcCtD
Doxepin—Asthenia—Epirubicin—testicular cancer	0.00016	0.000323	CcSEcCtD
Doxepin—Pruritus—Epirubicin—testicular cancer	0.000157	0.000319	CcSEcCtD
Doxepin—Dizziness—Methotrexate—testicular cancer	0.000157	0.000318	CcSEcCtD
Doxepin—Diarrhoea—Epirubicin—testicular cancer	0.000152	0.000308	CcSEcCtD
Doxepin—Hypersensitivity—Doxorubicin—testicular cancer	0.000152	0.000307	CcSEcCtD
Doxepin—Vomiting—Methotrexate—testicular cancer	0.000151	0.000306	CcSEcCtD
Doxepin—Rash—Methotrexate—testicular cancer	0.00015	0.000304	CcSEcCtD
Doxepin—Dermatitis—Methotrexate—testicular cancer	0.00015	0.000303	CcSEcCtD
Doxepin—Headache—Methotrexate—testicular cancer	0.000149	0.000302	CcSEcCtD
Doxepin—SLC6A2—NRF2 pathway—SLC2A6—testicular cancer	0.000148	0.026	CbGpPWpGaD
Doxepin—Asthenia—Doxorubicin—testicular cancer	0.000148	0.000299	CcSEcCtD
Doxepin—Dizziness—Epirubicin—testicular cancer	0.000147	0.000298	CcSEcCtD
Doxepin—Pruritus—Doxorubicin—testicular cancer	0.000146	0.000295	CcSEcCtD
Doxepin—Vomiting—Epirubicin—testicular cancer	0.000141	0.000287	CcSEcCtD
Doxepin—Nausea—Methotrexate—testicular cancer	0.000141	0.000286	CcSEcCtD
Doxepin—Diarrhoea—Doxorubicin—testicular cancer	0.000141	0.000285	CcSEcCtD
Doxepin—Rash—Epirubicin—testicular cancer	0.00014	0.000284	CcSEcCtD
Doxepin—Dermatitis—Epirubicin—testicular cancer	0.00014	0.000284	CcSEcCtD
Doxepin—Headache—Epirubicin—testicular cancer	0.000139	0.000282	CcSEcCtD
Doxepin—Dizziness—Doxorubicin—testicular cancer	0.000136	0.000276	CcSEcCtD
Doxepin—Nausea—Epirubicin—testicular cancer	0.000132	0.000268	CcSEcCtD
Doxepin—KCNH2—Hematopoietic Stem Cell Differentiation—KITLG—testicular cancer	0.000131	0.0231	CbGpPWpGaD
Doxepin—Vomiting—Doxorubicin—testicular cancer	0.000131	0.000265	CcSEcCtD
Doxepin—Rash—Doxorubicin—testicular cancer	0.00013	0.000263	CcSEcCtD
Doxepin—Dermatitis—Doxorubicin—testicular cancer	0.00013	0.000263	CcSEcCtD
Doxepin—Headache—Doxorubicin—testicular cancer	0.000129	0.000261	CcSEcCtD
Doxepin—HRH4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000122	0.0215	CbGpPWpGaD
Doxepin—Nausea—Doxorubicin—testicular cancer	0.000122	0.000248	CcSEcCtD
Doxepin—HRH2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	9.49e-05	0.0167	CbGpPWpGaD
Doxepin—HRH4—GPCR ligand binding—INSL3—testicular cancer	9.32e-05	0.0164	CbGpPWpGaD
Doxepin—SLC6A2—SLC-mediated transmembrane transport—SLC2A6—testicular cancer	9.31e-05	0.0164	CbGpPWpGaD
Doxepin—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	7.28e-05	0.0128	CbGpPWpGaD
Doxepin—HRH2—GPCR ligand binding—INSL3—testicular cancer	7.23e-05	0.0127	CbGpPWpGaD
Doxepin—CHRM4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.86e-05	0.0121	CbGpPWpGaD
Doxepin—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.64e-05	0.0117	CbGpPWpGaD
Doxepin—CHRM5—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.57e-05	0.0116	CbGpPWpGaD
Doxepin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	6.18e-05	0.0109	CbGpPWpGaD
Doxepin—CYP2C19—Arachidonic acid metabolism—HPGDS—testicular cancer	5.7e-05	0.01	CbGpPWpGaD
Doxepin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.58e-05	0.00981	CbGpPWpGaD
Doxepin—HTR6—GPCR ligand binding—INSL3—testicular cancer	5.54e-05	0.00974	CbGpPWpGaD
Doxepin—ADRA1B—AMPK Signaling—STK11—testicular cancer	5.47e-05	0.00962	CbGpPWpGaD
Doxepin—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.39e-05	0.00947	CbGpPWpGaD
Doxepin—HTR2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.36e-05	0.00942	CbGpPWpGaD
Doxepin—HRH4—GPCR downstream signaling—INSL3—testicular cancer	5.27e-05	0.00926	CbGpPWpGaD
Doxepin—CHRM4—GPCR ligand binding—INSL3—testicular cancer	5.23e-05	0.00919	CbGpPWpGaD
Doxepin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.21e-05	0.00916	CbGpPWpGaD
Doxepin—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	5.2e-05	0.00914	CbGpPWpGaD
Doxepin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	5.13e-05	0.00902	CbGpPWpGaD
Doxepin—HTR2B—GPCR ligand binding—INSL3—testicular cancer	5.06e-05	0.00889	CbGpPWpGaD
Doxepin—CHRM5—GPCR ligand binding—INSL3—testicular cancer	5.01e-05	0.0088	CbGpPWpGaD
Doxepin—ADRA1A—AMPK Signaling—STK11—testicular cancer	4.86e-05	0.00855	CbGpPWpGaD
Doxepin—HRH4—Signaling by GPCR—INSL3—testicular cancer	4.78e-05	0.00841	CbGpPWpGaD
Doxepin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	4.75e-05	0.00835	CbGpPWpGaD
Doxepin—SLC6A2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	4.73e-05	0.00831	CbGpPWpGaD
Doxepin—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.73e-05	0.00831	CbGpPWpGaD
Doxepin—ADRA1D—GPCR ligand binding—INSL3—testicular cancer	4.71e-05	0.00827	CbGpPWpGaD
Doxepin—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.65e-05	0.00818	CbGpPWpGaD
Doxepin—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.64e-05	0.00816	CbGpPWpGaD
Doxepin—CHRM1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.63e-05	0.00814	CbGpPWpGaD
Doxepin—CHRM3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.61e-05	0.00811	CbGpPWpGaD
Doxepin—CHRM2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.57e-05	0.00803	CbGpPWpGaD
Doxepin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.56e-05	0.00801	CbGpPWpGaD
Doxepin—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	4.44e-05	0.00781	CbGpPWpGaD
Doxepin—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	4.25e-05	0.00747	CbGpPWpGaD
Doxepin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	4.23e-05	0.00744	CbGpPWpGaD
Doxepin—HTR1A—GPCR ligand binding—INSL3—testicular cancer	4.1e-05	0.00721	CbGpPWpGaD
Doxepin—HRH2—GPCR downstream signaling—INSL3—testicular cancer	4.08e-05	0.00718	CbGpPWpGaD
Doxepin—HTR2C—GPCR ligand binding—INSL3—testicular cancer	4.08e-05	0.00717	CbGpPWpGaD
Doxepin—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	4.01e-05	0.00704	CbGpPWpGaD
Doxepin—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	3.97e-05	0.00698	CbGpPWpGaD
Doxepin—ADRA1B—GPCR ligand binding—INSL3—testicular cancer	3.91e-05	0.00687	CbGpPWpGaD
Doxepin—HRH2—Signaling by GPCR—INSL3—testicular cancer	3.71e-05	0.00652	CbGpPWpGaD
Doxepin—DRD2—GPCR ligand binding—INSL3—testicular cancer	3.6e-05	0.00633	CbGpPWpGaD
Doxepin—CHRM3—Integration of energy metabolism—STK11—testicular cancer	3.55e-05	0.00623	CbGpPWpGaD
Doxepin—HTR2A—GPCR ligand binding—INSL3—testicular cancer	3.54e-05	0.00623	CbGpPWpGaD
Doxepin—HRH1—GPCR ligand binding—INSL3—testicular cancer	3.54e-05	0.00622	CbGpPWpGaD
Doxepin—CHRM1—GPCR ligand binding—INSL3—testicular cancer	3.52e-05	0.0062	CbGpPWpGaD
Doxepin—CHRM3—GPCR ligand binding—INSL3—testicular cancer	3.51e-05	0.00618	CbGpPWpGaD
Doxepin—CHRM2—GPCR ligand binding—INSL3—testicular cancer	3.48e-05	0.00612	CbGpPWpGaD
Doxepin—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	3.47e-05	0.0061	CbGpPWpGaD
Doxepin—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	3.25e-05	0.00572	CbGpPWpGaD
Doxepin—ADRA1B—LPA receptor mediated events—MMP2—testicular cancer	3.25e-05	0.00572	CbGpPWpGaD
Doxepin—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	3.22e-05	0.00567	CbGpPWpGaD
Doxepin—HTR6—GPCR downstream signaling—INSL3—testicular cancer	3.13e-05	0.00551	CbGpPWpGaD
Doxepin—CHRM4—GPCR downstream signaling—INSL3—testicular cancer	2.95e-05	0.00519	CbGpPWpGaD
Doxepin—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	2.86e-05	0.00503	CbGpPWpGaD
Doxepin—HTR6—Signaling by GPCR—INSL3—testicular cancer	2.84e-05	0.005	CbGpPWpGaD
Doxepin—CHRM5—GPCR downstream signaling—INSL3—testicular cancer	2.83e-05	0.00497	CbGpPWpGaD
Doxepin—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	2.83e-05	0.00497	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—INSL3—testicular cancer	2.83e-05	0.00497	CbGpPWpGaD
Doxepin—CHRM4—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	2.72e-05	0.00478	CbGpPWpGaD
Doxepin—CHRM4—Signaling by GPCR—INSL3—testicular cancer	2.68e-05	0.00472	CbGpPWpGaD
Doxepin—ADRA1D—GPCR downstream signaling—INSL3—testicular cancer	2.66e-05	0.00468	CbGpPWpGaD
Doxepin—CHRM5—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	2.61e-05	0.00458	CbGpPWpGaD
Doxepin—HTR2B—Signaling by GPCR—INSL3—testicular cancer	2.6e-05	0.00456	CbGpPWpGaD
Doxepin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	2.59e-05	0.00456	CbGpPWpGaD
Doxepin—CHRM5—Signaling by GPCR—INSL3—testicular cancer	2.57e-05	0.00452	CbGpPWpGaD
Doxepin—ADRA1D—Signaling by GPCR—INSL3—testicular cancer	2.42e-05	0.00425	CbGpPWpGaD
Doxepin—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	2.4e-05	0.00422	CbGpPWpGaD
Doxepin—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	2.32e-05	0.00408	CbGpPWpGaD
Doxepin—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	2.31e-05	0.00405	CbGpPWpGaD
Doxepin—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	2.24e-05	0.00394	CbGpPWpGaD
Doxepin—ADRA1B—GPCR downstream signaling—INSL3—testicular cancer	2.21e-05	0.00388	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—INSL3—testicular cancer	2.19e-05	0.00385	CbGpPWpGaD
Doxepin—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	2.18e-05	0.00383	CbGpPWpGaD
Doxepin—CYP2C19—Biological oxidations—HPGDS—testicular cancer	2.12e-05	0.00373	CbGpPWpGaD
Doxepin—HTR1A—Signaling by GPCR—INSL3—testicular cancer	2.11e-05	0.0037	CbGpPWpGaD
Doxepin—HTR2C—Signaling by GPCR—INSL3—testicular cancer	2.09e-05	0.00368	CbGpPWpGaD
Doxepin—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	2.08e-05	0.00366	CbGpPWpGaD
Doxepin—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	2.04e-05	0.00358	CbGpPWpGaD
Doxepin—DRD2—GPCR downstream signaling—INSL3—testicular cancer	2.04e-05	0.00358	CbGpPWpGaD
Doxepin—ADRA1B—Signaling by GPCR—INSL3—testicular cancer	2e-05	0.00352	CbGpPWpGaD
Doxepin—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	2e-05	0.00352	CbGpPWpGaD
Doxepin—HRH1—GPCR downstream signaling—INSL3—testicular cancer	2e-05	0.00351	CbGpPWpGaD
Doxepin—CHRM1—GPCR downstream signaling—INSL3—testicular cancer	1.99e-05	0.0035	CbGpPWpGaD
Doxepin—CHRM3—GPCR downstream signaling—INSL3—testicular cancer	1.99e-05	0.00349	CbGpPWpGaD
Doxepin—CHRM2—GPCR downstream signaling—INSL3—testicular cancer	1.97e-05	0.00346	CbGpPWpGaD
Doxepin—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	1.96e-05	0.00345	CbGpPWpGaD
Doxepin—CYP2D6—Biological oxidations—HPGDS—testicular cancer	1.95e-05	0.00343	CbGpPWpGaD
Doxepin—CYP2C9—Biological oxidations—HPGDS—testicular cancer	1.93e-05	0.0034	CbGpPWpGaD
Doxepin—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	1.9e-05	0.00335	CbGpPWpGaD
Doxepin—DRD2—Signaling by GPCR—INSL3—testicular cancer	1.85e-05	0.00325	CbGpPWpGaD
Doxepin—CHRM1—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	1.83e-05	0.00323	CbGpPWpGaD
Doxepin—CHRM3—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	1.83e-05	0.00321	CbGpPWpGaD
Doxepin—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	1.82e-05	0.0032	CbGpPWpGaD
Doxepin—HTR2A—Signaling by GPCR—INSL3—testicular cancer	1.82e-05	0.0032	CbGpPWpGaD
Doxepin—HRH1—Signaling by GPCR—INSL3—testicular cancer	1.81e-05	0.00319	CbGpPWpGaD
Doxepin—CHRM2—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	1.81e-05	0.00318	CbGpPWpGaD
Doxepin—CHRM1—Signaling by GPCR—INSL3—testicular cancer	1.81e-05	0.00318	CbGpPWpGaD
Doxepin—CHRM3—Signaling by GPCR—INSL3—testicular cancer	1.8e-05	0.00317	CbGpPWpGaD
Doxepin—CHRM2—Signaling by GPCR—INSL3—testicular cancer	1.79e-05	0.00314	CbGpPWpGaD
Doxepin—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	1.78e-05	0.00313	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—INSL3—testicular cancer	1.68e-05	0.00295	CbGpPWpGaD
Doxepin—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	1.65e-05	0.00291	CbGpPWpGaD
Doxepin—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.65e-05	0.00291	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—INSL3—testicular cancer	1.58e-05	0.00279	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—INSL3—testicular cancer	1.53e-05	0.0027	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—INSL3—testicular cancer	1.52e-05	0.00267	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—INSL3—testicular cancer	1.43e-05	0.00251	CbGpPWpGaD
Doxepin—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.38e-05	0.00243	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—INSL3—testicular cancer	1.29e-05	0.00226	CbGpPWpGaD
Doxepin—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.28e-05	0.00224	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—INSL3—testicular cancer	1.24e-05	0.00219	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—INSL3—testicular cancer	1.24e-05	0.00217	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—INSL3—testicular cancer	1.2e-05	0.00212	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—INSL3—testicular cancer	1.18e-05	0.00208	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—INSL3—testicular cancer	1.09e-05	0.00192	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00189	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00188	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00188	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—INSL3—testicular cancer	1.07e-05	0.00187	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—INSL3—testicular cancer	1.05e-05	0.00185	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—INSL3—testicular cancer	1.05e-05	0.00185	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—INSL3—testicular cancer	9.77e-06	0.00172	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—H2AFZ—testicular cancer	9.04e-06	0.00159	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—STK11—testicular cancer	8.99e-06	0.00158	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—KITLG—testicular cancer	8.32e-06	0.00146	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.15e-06	0.00143	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.43e-06	0.00131	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—H2AFZ—testicular cancer	7.01e-06	0.00123	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—STK11—testicular cancer	6.97e-06	0.00123	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—KITLG—testicular cancer	6.45e-06	0.00113	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	6.35e-06	0.00112	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—HPGDS—testicular cancer	6.3e-06	0.00111	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—FGFR3—testicular cancer	6.18e-06	0.00109	CbGpPWpGaD
Doxepin—HRH4—Signaling Pathways—KIT—testicular cancer	5.68e-06	0.000998	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—HPGDS—testicular cancer	5.58e-06	0.000981	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—H2AFZ—testicular cancer	5.38e-06	0.000945	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—STK11—testicular cancer	5.35e-06	0.00094	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—HPGDS—testicular cancer	5.12e-06	0.0009	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—H2AFZ—testicular cancer	5.07e-06	0.000892	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—STK11—testicular cancer	5.04e-06	0.000887	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—KITLG—testicular cancer	4.95e-06	0.00087	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	4.91e-06	0.000863	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—STK11—testicular cancer	4.88e-06	0.000858	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—H2AFZ—testicular cancer	4.86e-06	0.000854	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—STK11—testicular cancer	4.83e-06	0.000849	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—FGFR3—testicular cancer	4.79e-06	0.000843	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—KITLG—testicular cancer	4.67e-06	0.00082	CbGpPWpGaD
Doxepin—ADRA2C—Metabolism—STK11—testicular cancer	4.58e-06	0.000805	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—H2AFZ—testicular cancer	4.57e-06	0.000803	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—STK11—testicular cancer	4.54e-06	0.000798	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—KITLG—testicular cancer	4.52e-06	0.000794	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—KITLG—testicular cancer	4.47e-06	0.000786	CbGpPWpGaD
Doxepin—HRH2—Signaling Pathways—KIT—testicular cancer	4.4e-06	0.000774	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—KITLG—testicular cancer	4.2e-06	0.000739	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	4.12e-06	0.000725	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—STK11—testicular cancer	4.1e-06	0.000721	CbGpPWpGaD
Doxepin—CHRM3—Metabolism—STK11—testicular cancer	4.05e-06	0.000713	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	3.98e-06	0.0007	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	3.96e-06	0.000696	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—STK11—testicular cancer	3.96e-06	0.000696	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—STK11—testicular cancer	3.94e-06	0.000692	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	3.85e-06	0.000677	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—STK11—testicular cancer	3.83e-06	0.000673	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KITLG—testicular cancer	3.79e-06	0.000667	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—H2AFZ—testicular cancer	3.79e-06	0.000666	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—STK11—testicular cancer	3.77e-06	0.000663	CbGpPWpGaD
Doxepin—ADRA2A—Metabolism—STK11—testicular cancer	3.72e-06	0.000654	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—FGFR3—testicular cancer	3.68e-06	0.000646	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KITLG—testicular cancer	3.66e-06	0.000644	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KITLG—testicular cancer	3.64e-06	0.00064	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—HPGDS—testicular cancer	3.63e-06	0.000638	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KITLG—testicular cancer	3.54e-06	0.000623	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—HPGDS—testicular cancer	3.54e-06	0.000622	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—H2AFZ—testicular cancer	3.5e-06	0.000614	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KITLG—testicular cancer	3.49e-06	0.000613	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—STK11—testicular cancer	3.48e-06	0.000611	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—FGFR3—testicular cancer	3.47e-06	0.00061	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	3.44e-06	0.000605	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—H2AFZ—testicular cancer	3.43e-06	0.000603	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—H2AFZ—testicular cancer	3.42e-06	0.000601	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—STK11—testicular cancer	3.42e-06	0.000601	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—STK11—testicular cancer	3.41e-06	0.0006	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—H2AFZ—testicular cancer	3.41e-06	0.000599	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—STK11—testicular cancer	3.4e-06	0.000598	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—STK11—testicular cancer	3.39e-06	0.000596	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—H2AFZ—testicular cancer	3.38e-06	0.000594	CbGpPWpGaD
Doxepin—HTR6—Signaling Pathways—KIT—testicular cancer	3.38e-06	0.000593	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	3.37e-06	0.000592	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—STK11—testicular cancer	3.36e-06	0.00059	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—FGFR3—testicular cancer	3.36e-06	0.00059	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—STK11—testicular cancer	3.35e-06	0.000589	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—HPGDS—testicular cancer	3.34e-06	0.000587	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—FGFR3—testicular cancer	3.32e-06	0.000584	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—HPGDS—testicular cancer	3.31e-06	0.000581	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KITLG—testicular cancer	3.22e-06	0.000565	CbGpPWpGaD
Doxepin—CHRM4—Signaling Pathways—KIT—testicular cancer	3.18e-06	0.00056	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KITLG—testicular cancer	3.16e-06	0.000556	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KITLG—testicular cancer	3.16e-06	0.000555	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KITLG—testicular cancer	3.15e-06	0.000553	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KITLG—testicular cancer	3.14e-06	0.000551	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	3.13e-06	0.00055	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—FGFR3—testicular cancer	3.12e-06	0.000549	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—STK11—testicular cancer	3.11e-06	0.000547	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KITLG—testicular cancer	3.11e-06	0.000546	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KITLG—testicular cancer	3.1e-06	0.000545	CbGpPWpGaD
Doxepin—HTR2B—Signaling Pathways—KIT—testicular cancer	3.08e-06	0.000542	CbGpPWpGaD
Doxepin—CHRM5—Signaling Pathways—KIT—testicular cancer	3.05e-06	0.000536	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KITLG—testicular cancer	2.88e-06	0.000506	CbGpPWpGaD
Doxepin—ADRA1D—Signaling Pathways—KIT—testicular cancer	2.87e-06	0.000504	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—HPGDS—testicular cancer	2.83e-06	0.000497	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	2.82e-06	0.000496	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—FGFR3—testicular cancer	2.72e-06	0.000478	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—FGFR3—testicular cancer	2.71e-06	0.000476	CbGpPWpGaD
Doxepin—CYP2C19—Metabolism—STK11—testicular cancer	2.64e-06	0.000463	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	2.63e-06	0.000463	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—FGFR3—testicular cancer	2.59e-06	0.000456	CbGpPWpGaD
Doxepin—ADRA2B—Signaling Pathways—KIT—testicular cancer	2.59e-06	0.000455	CbGpPWpGaD
Doxepin—ABCB1—Metabolism—STK11—testicular cancer	2.57e-06	0.000452	CbGpPWpGaD
Doxepin—HTR1A—Signaling Pathways—KIT—testicular cancer	2.5e-06	0.000439	CbGpPWpGaD
Doxepin—HTR2C—Signaling Pathways—KIT—testicular cancer	2.49e-06	0.000437	CbGpPWpGaD
Doxepin—CYP2D6—Metabolism—STK11—testicular cancer	2.42e-06	0.000426	CbGpPWpGaD
Doxepin—ADRA2C—Signaling Pathways—KIT—testicular cancer	2.42e-06	0.000425	CbGpPWpGaD
Doxepin—CYP2C9—Metabolism—STK11—testicular cancer	2.4e-06	0.000422	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—FGFR3—testicular cancer	2.39e-06	0.00042	CbGpPWpGaD
Doxepin—ADRA1B—Signaling Pathways—KIT—testicular cancer	2.38e-06	0.000418	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—FGFR3—testicular cancer	2.35e-06	0.000413	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—FGFR3—testicular cancer	2.35e-06	0.000412	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—FGFR3—testicular cancer	2.34e-06	0.000411	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—FGFR3—testicular cancer	2.33e-06	0.00041	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—FGFR3—testicular cancer	2.31e-06	0.000406	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	2.3e-06	0.000405	CbGpPWpGaD
Doxepin—DRD2—Signaling Pathways—KIT—testicular cancer	2.19e-06	0.000386	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—HPGDS—testicular cancer	2.18e-06	0.000383	CbGpPWpGaD
Doxepin—HTR2A—Signaling Pathways—KIT—testicular cancer	2.16e-06	0.00038	CbGpPWpGaD
Doxepin—HRH1—Signaling Pathways—KIT—testicular cancer	2.15e-06	0.000379	CbGpPWpGaD
Doxepin—CHRM1—Signaling Pathways—KIT—testicular cancer	2.15e-06	0.000377	CbGpPWpGaD
Doxepin—CHRM3—Signaling Pathways—KIT—testicular cancer	2.14e-06	0.000376	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	2.14e-06	0.000376	CbGpPWpGaD
Doxepin—CHRM2—Signaling Pathways—KIT—testicular cancer	2.12e-06	0.000373	CbGpPWpGaD
Doxepin—ADRA1A—Signaling Pathways—KIT—testicular cancer	2.11e-06	0.000372	CbGpPWpGaD
Doxepin—CYP1A2—Metabolism—STK11—testicular cancer	2.05e-06	0.000361	CbGpPWpGaD
Doxepin—ADRA2A—Signaling Pathways—KIT—testicular cancer	1.96e-06	0.000345	CbGpPWpGaD
Doxepin—CYP3A4—Metabolism—STK11—testicular cancer	1.58e-06	0.000279	CbGpPWpGaD
